MM patients who progressed after daratumumab treatment had elevated levels of the complement inhibitors CD55 and CD59, in agreement with the hypothesis that CDC represents a major mechanism of action for daratumumab and suggesting a mechanism of resistance to CDC-mediating antibodies. The gene discussed is CD59; the disease is Miyoshi myopathy.